Jacinth Joseph is an Oncology physician affiliated with UPMC Hillman Cancer Center. OpenAlex indexes 33 publications with 417 citations (h-index 12).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
7777 Forest Ln Ste D220
Dallas, TX 752302571
Telephone
972-566-7790Provider last certified this registry record 23 Feb 2024.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Astellas Pharma US IncProgram year20253 payments
- Geron CorporationProgram year20251 payment
- Astellas Pharma US IncProgram year20246 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
52.6%Serotonin-3 Receptor Antagonist50.2%Granisetron hydrochloride51%Ondansetron hydrochloride45%Ondansetron Hcl4%Part D + Part B<11 patientsCorticosteroid1.4%Prednisone100%Part D<11 patients+ 1 more class in this area
Sensory organs
30.1%Corticosteroid30.1%Dexamethasone sodium phosphate92%Dexamethasone8%Part D + Part B<11 patientsCancer & immunology
4.8%Aromatase Inhibitor3.8%Letrozole58%Anastrozole42%Part D<11 patientsAntimetabolite1%Hydroxyurea100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning
Biology of Blood and Marrow Transplantation
2023 - CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges
Blood and Lymphatic Cancer Targets and Therapy
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Udai Kammula, MD
UPMC Hillman Cancer Center
Amer Zureikat, MD
UPMC Hillman Cancer Center
Antoinette Wozniak, MD
UPMC Hillman Cancer Center
Mounzer Agha, MD
UPMC Hillman Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”